Balaji Gandhi Sells 3,502 Shares of Phreesia, Inc. (NYSE:PHR) Stock

Phreesia, Inc. (NYSE:PHR) CFO Balaji Gandhi sold 3,502 shares of Phreesia stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $23.25, for a total transaction of $81,421.50. Following the sale, the chief financial officer now directly owns 98,578 shares of the company’s stock, valued at approximately $2,291,938.50. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Balaji Gandhi also recently made the following trade(s):

• On Tuesday, July 16th, Balaji Gandhi sold 783 shares of Phreesia stock. The stock was sold at an average price of $23.74, for a total value of $18,588.42.

Phreesia Stock Performance

PHR opened at $24.68 on Friday. The stock’s 50 day simple moving average is $23.72 and its 200-day simple moving average is $22.75. The company has a current ratio of 1.77, a quick ratio of 1.77 and a debt-to-equity ratio of 0.03. The stock has a market cap of $1.42 billion, a PE ratio of -11.37 and a beta of 0.93. Phreesia, Inc. has a 1 year low of $12.05 and a 1 year high of $29.16.

Analysts Set New Price Targets

Several research analysts have weighed in on PHR shares. KeyCorp dropped their target price on Phreesia from $27.00 to $25.00 and set an “overweight” rating on the stock in a research report on Thursday, July 11th. Truist Financial raised their price objective on shares of Phreesia from $29.00 to $31.00 and gave the company a “buy” rating in a research report on Friday, September 6th. DA Davidson reissued a “buy” rating and issued a $32.00 target price on shares of Phreesia in a research report on Thursday, September 5th. Robert W. Baird raised their price target on shares of Phreesia from $31.00 to $34.00 and gave the company an “outperform” rating in a report on Friday, September 6th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $29.00 price objective on shares of Phreesia in a report on Thursday, September 5th. One research analyst has rated the stock with a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $29.42.

Institutional Investors Weigh In On Phreesia

Several institutional investors and hedge funds have recently bought and sold shares of PHR. nVerses Capital LLC lifted its holdings in shares of Phreesia by 76.5% during the 2nd quarter. nVerses Capital LLC now owns 3,000 shares of the company’s stock worth $64,000 after acquiring an additional 1,300 shares during the period. Russell Investments Group Ltd. lifted its stake in Phreesia by 5,462.3% during the fourth quarter. Russell Investments Group Ltd. now owns 3,838 shares of the company’s stock worth $89,000 after purchasing an additional 3,769 shares during the period. EntryPoint Capital LLC acquired a new stake in Phreesia during the first quarter valued at approximately $169,000. Quadrature Capital Ltd bought a new stake in shares of Phreesia in the 1st quarter valued at approximately $202,000. Finally, Lombard Odier Asset Management USA Corp acquired a new position in shares of Phreesia in the 2nd quarter worth approximately $202,000. Institutional investors own 92.10% of the company’s stock.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.